Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine eye drops used for treating and preventing glaucoma and preparation method

A technology for eye drops and glaucoma, applied in the field of vaccines, achieves low cost, promotes survival and regeneration, and is easy to accept

Inactive Publication Date: 2010-05-26
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Risk of experimental autoimmune encephalomyelitis (EAE) if dose is increased

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine eye drops used for treating and preventing glaucoma and preparation method
  • Vaccine eye drops used for treating and preventing glaucoma and preparation method
  • Vaccine eye drops used for treating and preventing glaucoma and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] Preparation of Example 1 Nogo66-CS Vaccine Eye Drops

[0120] Under sterile conditions, take 1.5mg / ml Nogo66 protein solution (Xie Lin, He Xiangge, Su Yueyue, etc., "Prokaryotic expression and identification of Nogo-66 fusion protein", "Journal of Immunology", 2005, 21(3): 251 )0.1ml, 0.5ml, 1.0ml, 1.5ml, add 1.4ml, 1ml, 0.5ml, 0ml of double distilled water respectively, and make 0.1mg / ml, 0.5mg / ml, 1.0mg / ml, 1.5mg / ml Nogo66 protein solution. Take another 10mg, 50mg, 100mg, 150mg of chitosan, add 10ml of double distilled water respectively, drop an appropriate amount of acetic acid to dissolve it completely, and prepare 1mg / ml, 5mg / ml, 10mg / ml, 15mg / ml chitosan solutions . The above-mentioned Nogo66 protein solution and chitosan solution were filtered 3-5 times with a 0.22 μm sterile microporous filter, respectively, and sterilized.

[0121] Mix the above-mentioned 0.1mg / ml Nogo66 protein solution and 1mg / ml chitosan solution in equal volumes after sterilization, sti...

Embodiment 2

[0127] Example 2 General inspection

[0128] 1. Properties: light yellow, slightly viscous and clear liquid

[0129] 2. PH value: The pH values ​​of A, B, C, and DNogo66-CS vaccine eye drops samples measured by a pH detector were 7.014, 7.127, 7.046, and 7.068, respectively.

[0130] 3. Osmotic pressure: Take 3 samples of Nogo66-CS vaccine eye drops of 4 concentrations and 3 samples of 0.9% NaCl solution, respectively, and test the osmotic pressure respectively. Results A, B, C, D The average osmotic pressure of Nogo66-CS vaccine eye drops samples were: 285mosm / L, 286mosm / L, 291mosm / L, 299mosm / L, and the average osmotic pressure of 0.9% NaCl solution samples was 301mosm / L . A, B, C, D The osmotic pressure of Nogo66-CS vaccine eye drops is equivalent to 0.95-0.99 times the osmotic pressure of 0.9% NaCl solution, which meets the requirements of eye drop preparations.

[0131] 4. Content determination: Precisely prepare bovine serum albumin solutions with concentrations of 0.2...

Embodiment 3

[0133] Example 3 Nogo66-CS vaccine eye solution acute eye irritation, corrosion test

[0134] Select 10 healthy adult SD rats with normal eyes and corneal fluorescein examination. Rats were anesthetized by intraperitoneal injection of 3% pentobarbital sodium at 1.3ml / kg. After the anesthesia was complete, the head of the animal was tilted to the left, the right eye was obliquely upward, and the double eyelids were gently lifted. A, B, C, and D Nogo66 -CS was instilled on the cornea of ​​the right eye with 0.05ml, once / 10min, and lasted for 1 hour for a total of 6 times; at the same time, the left eye was given normal saline with the same strategy as the control eye. Observation at the time of drug application and 1h, 24h, 48h, 72h and the 4th and 7th day after drug application: tears and secretions, conjunctival congestion and edema, conjunctival follicular papilla, corneal edema and turbidity, corneal punctate epithelial damage, Iris damage. And score according to the eye i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to vaccine eye drops used for treating and preventing glaucoma, which are characterized in that the eye drops comprise Nogo66 protein and chitosan, wherein the volume ratio of the Nogo66 protein to the chitosan is 1:1, the concentration of the Nogo66 protein is 0.1-1.5mg / ml, and the concentration of chitosan is 1-15mg / ml. The vaccine eye drops are used for optic nerve injury caused by the apoptosis or the traumatism of retina ganglionic cells caused by the glaucoma, can effectively improve the micro-environment of the injured neuron, induce the restoration and regeneration of the neuron and have the advantages of safe use, low price and convenient inoculation.

Description

technical field [0001] The invention relates to a vaccine, in particular to a vaccine eye drop for treating and preventing glaucoma and a preparation method. Background technique [0002] Glaucoma, the second leading cause of blindness in the world, can cause irreversible apoptosis of retinal ganglion cells (RGCs) and optic atrophy, eventually leading to blindness. Optic nerve injury is also a common type of trauma and cause of blindness in clinical practice. Various other ocular diseases such as optic neuritis, ischemic optic neuropathy, retinal vascular occlusion, and retinal degenerative diseases can all affect the optic nerve and lead to optic atrophy and eventually blindness. At present, the main treatment for glaucoma is to lower the intraocular pressure with drugs or surgery; however, even if the causes such as high intraocular pressure are removed, the loss of retinal ganglion cells and optic nerve atrophy still continue, and conventional intraocular hypotensive ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K9/08A61K47/36A61P27/06
Inventor 贺翔鸽程茗谢琳岳红云
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com